Overview
TXG market data
Price History
TXG price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.35 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.03 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $11.16 – $49.84 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $6.3K · P/B 2.59 · P/S 9.82.
Company News
10x Genomics Partners With Lausanne University Hospital On Diagnostic Applications Of Single Cell And Spatial Technologies For Cancer CareBenzinga · Jul 29, 2026, 1:05 PM
New AI ETF Bets on Healthcare's $9 Trillion OpportunityBenzinga · Jul 24, 2026, 7:08 PM
Leerink Partners Maintains Market Perform on 10x Genomics, Raises Price Target to $40Benzinga · Jul 17, 2026, 6:10 PM
Bioinformatics Collaboration and Licensing Deals 2019-2026 | Compare Upfronts, Milestones, and Royalties for 1,230+ DealsGlobenewswire Inc · Jul 17, 2026, 11:15 AM
Top 3 Health Care Stocks That May Implode This MonthBenzinga · Jul 15, 2026, 12:56 PM
10x Genomic shares are trading higher after Canaccord Genuity maintained a Buy rating on the stock and raised its price target from $32 to $50.Benzinga · Jul 14, 2026, 2:22 PM
Canaccord Genuity Maintains Buy on 10x Genomics, Raises Price Target to $50Benzinga · Jul 14, 2026, 12:01 PM
Morgan Stanley Maintains Equal-Weight on 10x Genomics, Raises Price Target to $37Benzinga · Jul 9, 2026, 4:40 PM
Citigroup Maintains Neutral on 10x Genomics, Raises Price Target to $45Benzinga · Jul 8, 2026, 4:10 PM
Piper Sandler Maintains Neutral on 10x Genomics, Raises Price Target to $42Benzinga · Jul 1, 2026, 1:30 PM